CAR-T Therapies
Solid Tumors
About BioArdis
BioArdis is a private, pre-clinical stage biotech company developing novel therapies for oncology, with a unique dual-platform strategy encompassing small molecules and CAR-T cell therapies. Its pipeline includes four pre-clinical small molecule programs and two CAR-T candidates undergoing IND-enabling studies, all aimed at challenging cancer indications, particularly solid tumors. The company is led by a seasoned management team with deep expertise in drug discovery, cell therapy, and operations, positioning it to advance its innovative candidates toward the clinic.
View full company profileAbout BioArdis
BioArdis is a private, pre-clinical stage biotech company developing novel therapies for oncology, with a unique dual-platform strategy encompassing small molecules and CAR-T cell therapies. Its pipeline includes four pre-clinical small molecule programs and two CAR-T candidates undergoing IND-enabling studies, all aimed at challenging cancer indications, particularly solid tumors. The company is led by a seasoned management team with deep expertise in drug discovery, cell therapy, and operations, positioning it to advance its innovative candidates toward the clinic.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| GSK4362676 | GSK plc | Phase 1 |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| ABBV-154 | AbbVie | Phase 1 |
| TAK-981 | Takeda Pharmaceutical | Phase 1/2 |
| TAK-676 | Takeda Pharmaceutical | Phase 1 |
| TAK-573 | Takeda Pharmaceutical | Phase 1 |
| TAK-164 | Takeda Pharmaceutical | Phase 1 |
| SHR-1316 | Jiangsu Hengrui Medicine | Phase 1/2 |
| BAY 2927088 | Bayer | Phase 1 |
| ASP1929 | Astellas Pharma | Phase 2 |
| IBI188 | Innovent Biologics | Phase 1 |
| Bispecific Antibody | Akeso | Phase 1/2 |